<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422018</url>
  </required_header>
  <id_info>
    <org_study_id>KC11MISI0439</org_study_id>
    <nct_id>NCT01422018</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To evaluate the efficacy of intravitreal bevacizumab (IVB) on focal edema with hard
      exudates secondary to diabetic retinopathy.

      Design: Prospective interventional case series. Participants: Ten eyes of 10 consecutive
      patients showing focal edema with hard exudates secondary to diabetic retinopathy which are
      not eligible for focal laser photocoagulation due to central location (&lt; 500 µm from fovea).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in best-corrected visual acuity (BCVA)</measure>
    <time_frame>from month 0 to month 6 in monthly schedule (upto 6 months)</time_frame>
    <description>ETDRS BCVA will be measured after 6 6 serial IVB.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>amount of hard exudates detected on fundus photography</measure>
    <time_frame>from month 0 to month 6 in bimonthly schedule (upto 6 months)</time_frame>
    <description>on fundus photography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular edema detected by optical coherent tomography</measure>
    <time_frame>from month 0 to month 6 in bimonthly schedule (upto 6 months)</time_frame>
    <description>central subfield thickness will be measured.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>one arm for Anastin injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal Avastin injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin (bevacizumab)</intervention_name>
    <description>Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)</description>
    <arm_group_label>one arm for Anastin injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients of either gender aged &gt; 18 years

          2. patients with type 2 diabetes

          3. central macular thickness &gt; 300 µm on OCT

          4. eyes not eligible for focal laser photocoagulation due to the central location of hard
             exudates (&lt; 500 µm)

          5. an area of retinal thickening less than 2 disc areas in diameter

          6. 67% or more of leakage associated with microaneurysms

        Exclusion Criteria:

          1. eyes with history of laser photocoagulation or pharmacological intervention for DME on
             study eye

          2. eyes with any pharmacologic intervention on fellow eye within 6 months

          3. history of ocular diseases other than diabetic retinopathy

          4. surgical history other than cataract extraction with intraocular lens implantation

          5. panretinal photocoagulation within 3 months of enrollment

          6. media opacity

          7. any thromboembolic event within 6 months, or evidence of active cardiac ischemia on
             electrocardiogram (ECG) at time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won ki Lee, MD Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohee Jeon, MD</last_name>
    <phone>82-10-7176-1357</phone>
    <email>soheeeee@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Won ki Lee, DM, Ph.D</last_name>
    <phone>82-2-2258-1188</phone>
    <email>wklee@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul St Mary's hospital</name>
      <address>
        <city>Seocho</city>
        <state>Seoul</state>
        <zip>137-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohee Jeon, MD</last_name>
      <phone>82-10-7176-1357</phone>
      <email>soheeeee@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <last_update_submitted>September 22, 2011</last_update_submitted>
  <last_update_submitted_qc>September 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Won Ki Lee</investigator_full_name>
    <investigator_title>Pf.</investigator_title>
  </responsible_party>
  <keyword>clinically significant macular edema</keyword>
  <keyword>diabetic macular edema</keyword>
  <keyword>focal edema</keyword>
  <keyword>focal laser photocoagulation</keyword>
  <keyword>hard exudates</keyword>
  <keyword>intravitreal bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

